Bioatla (BCAB) Q2 2024 earnings summary

Executive summary

• Significant clinical progress in Q2 2024, including FDA Fast Track designation for ozuriftamab vedotin in refractory head and neck cancer, and promising data updates across the pipeline.

• Ongoing Phase 2 and Phase 1 trials for lead candidates, with key data readouts and regulatory milestones anticipated in the second half of 2024.

• Strategic partnership discussions are advancing, with confidence in establishing collaborations in 2024.

• Net loss for Q2 2024 was $21.1 million, improved from $35.8 million in Q2 2023, and cash and cash equivalents stood at $61.7 million as of June 30, 2024.

• The company has an accumulated deficit of $460.6 million and expects continued operating losses as it advances clinical programs.

Financial highlights

• Research and development expenses were $16.2 million for Q2 2024, down from $31 million in Q2 2023, mainly due to completion of preclinical development and clinical program prioritization.

• General and administrative expenses decreased to $5.8 million from $6.2 million year-over-year, primarily due to lower stock-based compensation and insurance costs.

• Net loss for Q2 2024 was $21.1 million, compared to $35.8 million in Q2 2023.

• Cash and cash equivalents stood at $61.7 million as of June 30, 2024, down from $111.5 million at year-end 2023.

• Net cash used in operating activities for the first half of 2024 was $50 million, up from $46.7 million in the same period last year.

Outlook and guidance

• R&D expenses are expected to decrease further as phase 2 clinical trials conclude and FDA meetings occur for potential registrational trials.

• Current cash position projected to fund operations through Q3 2025, supporting multiple clinical readouts and positioning for registration trials.

• Substantial additional capital will be required to complete development and commercialization of product candidates.

• Anticipated data presentations at ESMO in September and other conferences later in the year.